JP2018512110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512110A5 JP2018512110A5 JP2017534297A JP2017534297A JP2018512110A5 JP 2018512110 A5 JP2018512110 A5 JP 2018512110A5 JP 2017534297 A JP2017534297 A JP 2017534297A JP 2017534297 A JP2017534297 A JP 2017534297A JP 2018512110 A5 JP2018512110 A5 JP 2018512110A5
- Authority
- JP
- Japan
- Prior art keywords
- deoxy
- nucleotide
- nucleic acid
- antisense strand
- positions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000692 anti-sense Effects 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 4
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 3
- 229920000972 Sense strand Polymers 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000006011 modification reaction Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 102100009279 KRAS Human genes 0.000 claims 1
- 101710033922 KRAS Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000009030 carcinoma Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 125000001921 locked nucleotide group Chemical group 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical class [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Claims (9)
- センス鎖及びアンチセンス鎖を含むGST-πの発現を阻害する核酸分子であって、前記鎖が二重鎖領域を形成し、前記アンチセンス鎖は配列番号１５７のヌクレオチド配列又は修飾を有する当該ヌクレオチド鎖を含み、前記センス鎖は配列番号１３１のヌクレオチド配列又は修飾を有する当該ヌクレオチド鎖を含む（これらヌクレオチド配列において、A、G、C及びUはそれぞれリボA、リボG、リボC及びリボUであり、NはA、C、G、U、2'-OMe置換U、a、c、g、u、t、修飾ヌクレオチド、逆方向（inverted）ヌクレオチド又は化学修飾ヌクレオチドである（a、c、g、u及びtはそれぞれ2'-デオキシ-A、2'-デオキシ-C、2'-デオキシ-G、2'-デオキシ-U及び2'-デオキシ-T））、核酸分子。
- 前記修飾が、2’-デオキシヌクレオチド、2’-O-アルキル置換ヌクレオチド、2’-デオキシ-2’-フルオロ置換ヌクレオチド、ホスホロチオエートヌクレオチド、ロックドヌクレオチド又はそれらの任意の組み合わせである、請求項１記載の核酸分子。
- 前記アンチセンス鎖が複数の位置にデオキシヌクレオチドを有し、前記複数の位置が以下のうちの1つである、請求項１記載の核酸分子。
アンチセンス鎖の5’末端からの位置4、6及び8のそれぞれ;
アンチセンス鎖の5’末端からの位置3、5及び7のそれぞれ;
アンチセンス鎖の5’末端からの位置1、3、5及び7のそれぞれ;
アンチセンス鎖の5’末端からの位置3〜8のそれぞれ;又は
アンチセンス鎖の5’末端からの位置5〜8のそれぞれ - 前記二重鎖領域内に1つ以上の2'-デオキシ-2'-フルオロ置換ヌクレオチドを有する、請求項１記載の核酸分子。
- 上記アンチセンス鎖及び上記センス鎖は、下記表のIDで示される組み合わせであることを特徴とする請求項１記載の核酸分子。
- 請求項１〜５いずれか１項記載の核酸分子及び薬学的に許容される担体を含む医薬組成物。
- 前記担体が脂質分子又はリポソームを含む、請求項６記載の医薬組成物。
- 悪性腫瘍、癌、突然変異KRASを発現する細胞に起因する癌、肉腫及び癌腫から選ばれる少なくとも一種に対する治療のための請求項６記載の医薬組成物。
- 請求項１〜５いずれか１項記載の核酸分子を含むベクター又は細胞。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014266198 | 2014-12-26 | ||
| JP2014266198 | 2014-12-26 | ||
| US201562184239P | 2015-06-24 | 2015-06-24 | |
| US62/184,239 | 2015-06-24 | ||
| US201562266664P | 2015-12-13 | 2015-12-13 | |
| US62/266,664 | 2015-12-13 | ||
| PCT/US2015/067553 WO2016106400A2 (en) | 2014-12-26 | 2015-12-28 | Rna interference agents for gst-pi gene modulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018134405A Division JP6600389B2 (ja) | 2014-12-26 | 2018-07-17 | ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512110A JP2018512110A (ja) | 2018-05-17 |
| JP2018512110A5 true JP2018512110A5 (ja) | 2018-08-30 |
| JP6457645B2 JP6457645B2 (ja) | 2019-01-23 |
Family
ID=56151549
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534275A Pending JP2018512373A (ja) | 2014-12-26 | 2015-12-28 | Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物 |
| JP2017534274A Pending JP2018513104A (ja) | 2014-12-26 | 2015-12-28 | Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法 |
| JP2017534294A Active JP6730285B2 (ja) | 2014-12-26 | 2015-12-28 | Ｒｎａ干渉組成物及び悪性腫瘍のための方法 |
| JP2017534286A Active JP6793649B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ剤 |
| JP2017534287A Pending JP2018513669A (ja) | 2014-12-26 | 2015-12-28 | Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤 |
| JP2017534279A Active JP6865169B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ干渉剤 |
| JP2017534297A Active JP6457645B2 (ja) | 2014-12-26 | 2015-12-28 | ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2021183788A Active JP7307137B2 (ja) | 2014-12-26 | 2021-11-11 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2023106970A Pending JP2023123743A (ja) | 2014-12-26 | 2023-06-29 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534275A Pending JP2018512373A (ja) | 2014-12-26 | 2015-12-28 | Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物 |
| JP2017534274A Pending JP2018513104A (ja) | 2014-12-26 | 2015-12-28 | Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法 |
| JP2017534294A Active JP6730285B2 (ja) | 2014-12-26 | 2015-12-28 | Ｒｎａ干渉組成物及び悪性腫瘍のための方法 |
| JP2017534286A Active JP6793649B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ剤 |
| JP2017534287A Pending JP2018513669A (ja) | 2014-12-26 | 2015-12-28 | Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤 |
| JP2017534279A Active JP6865169B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ干渉剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021183788A Active JP7307137B2 (ja) | 2014-12-26 | 2021-11-11 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2023106970A Pending JP2023123743A (ja) | 2014-12-26 | 2023-06-29 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (14) | US10264976B2 (ja) |
| EP (9) | EP3798308A1 (ja) |
| JP (9) | JP2018512373A (ja) |
| KR (4) | KR20170093988A (ja) |
| CN (7) | CN107106564A (ja) |
| AU (4) | AU2015369592B2 (ja) |
| BR (2) | BR112017013599A2 (ja) |
| CA (4) | CA2971881C (ja) |
| RU (4) | RU2017126601A (ja) |
| WO (7) | WO2016106405A1 (ja) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10792299B2 (en) | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| ES2789049T3 (es) * | 2014-12-26 | 2020-10-23 | Nitto Denko Corp | Agentes de interferencia de ARN para modulación génica de GST-pi |
| US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| US11045488B2 (en) | 2014-12-26 | 2021-06-29 | Nitto Denko Corporation | RNA interference agents for GST-π gene modulation |
| US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| AU2016281685B2 (en) * | 2015-06-24 | 2021-08-12 | Nitto Denko Corporation | Ionizable compounds and compositions and uses thereof |
| PT3386519T (pt) | 2015-12-13 | 2021-04-27 | Nitto Denko Corp | Estruturas de sirna para atividade elevada e redução de alvos extra |
| WO2018151840A2 (en) * | 2017-02-16 | 2018-08-23 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors |
| KR20200084338A (ko) * | 2017-11-06 | 2020-07-10 | 닛토덴코 가부시키가이샤 | 생물학적 활성 분자의 전달을 위한 융합성 화합물 |
| CN111315882A (zh) * | 2017-11-09 | 2020-06-19 | 国立大学法人东京医科齿科大学 | 癌症促进因子表达抑制剂、其有效成分的筛选方法、对该方法有用的表达盒、诊断药和诊断方法 |
| CN109777798A (zh) * | 2017-11-13 | 2019-05-21 | 深圳华大生命科学研究院 | 一种基于CRISPR技术治疗KRAS突变恶性肿瘤的sgRNA及其应用 |
| JP6952594B2 (ja) * | 2017-12-15 | 2021-10-20 | 洋司郎 新津 | 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物 |
| CN108486011B (zh) * | 2018-03-27 | 2020-05-05 | 山东大学 | 一种三联苯化合物、制备方法及其应用 |
| JP7432929B2 (ja) * | 2018-05-31 | 2024-02-19 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | マイクロｒｎａの非正規標的を抑制するｒｎａ干渉誘導核酸およびその用途 |
| WO2020009189A1 (ja) * | 2018-07-05 | 2020-01-09 | 洋司郎 新津 | Ｂｒａｆ阻害剤によるがん細胞の逆説的増殖を抑制する薬剤 |
| US20210260095A1 (en) * | 2018-08-22 | 2021-08-26 | Nitto Denko Corporation | Medicine using hsp47 inhibitor to enhance sensitivity to chemotherapeutic agent |
| EP3851125A4 (en) * | 2018-08-22 | 2022-08-17 | Nitto Denko Corporation | DRUG USING AN HSP47 INHIBITOR TO SUPPRESS METASTASIS |
| JP2022512077A (ja) * | 2018-11-16 | 2022-02-02 | 日東電工株式会社 | Ｒｎａ干渉送達製剤及び悪性腫瘍のための方法 |
| JPWO2020116537A1 (ja) * | 2018-12-05 | 2021-10-21 | 日東電工株式会社 | がん処置用ＲＮＡｉ分子 |
| JP7373807B2 (ja) | 2019-01-10 | 2023-11-06 | 国立大学法人大阪大学 | 免疫賦活用組成物 |
| CN113677373A (zh) * | 2019-03-28 | 2021-11-19 | 日东电工株式会社 | RNAi分子 |
| JP2019116507A (ja) * | 2019-04-25 | 2019-07-18 | 有限会社オービット | Ｈｓｐ４７の発現促進剤、脱毛抑制方法、Ｈｓｐ４７の発現促進剤の製造方法及び飲食物の製造方法 |
| WO2021020412A1 (ja) * | 2019-07-30 | 2021-02-04 | 塩野義製薬株式会社 | Ｍｕｒｆ１を標的とする核酸医薬 |
| CN112280800B (zh) * | 2020-10-19 | 2022-06-07 | 上海市东方医院（同济大学附属东方医院） | 一种构建体及其在制备动物衰老细胞示踪和衰老细胞清除药物中的应用 |
| EP4267741A2 (en) | 2020-12-28 | 2023-11-01 | 1E Therapeutics, Ltd. | P21 mrna target areas for silencing |
| AU2021416356A1 (en) | 2020-12-28 | 2023-08-10 | 1E Therapeutics, Ltd. | P21 mrna targeting dnazymes |
| KR20230101286A (ko) * | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR20230101285A (ko) * | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR20230101283A (ko) * | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR20230101284A (ko) * | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR20230101287A (ko) * | 2021-12-29 | 2023-07-06 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| WO2023210713A1 (ja) * | 2022-04-27 | 2023-11-02 | 国立大学法人京都大学 | 心外膜細胞再生促進剤および心外膜細胞の再生促進方法 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU630076B2 (en) | 1987-09-21 | 1992-10-22 | Gen-Probe Incorporated | Non-nucleotide linking reagents for nucleotide probes |
| US5204241A (en) | 1990-10-22 | 1993-04-20 | Oxi-Gene Inc. | Glutathione-S-transferase mu as a measure of drug resistance |
| US5786336A (en) | 1991-04-29 | 1998-07-28 | Terrapin Technologies, Inc. | Target-selective protocols based on mimics |
| US5658780A (en) | 1992-12-07 | 1997-08-19 | Ribozyme Pharmaceuticals, Inc. | Rel a targeted ribozymes |
| EP0748382B1 (en) | 1993-09-02 | 2002-11-06 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
| ES2127948T3 (es) | 1993-10-27 | 1999-05-01 | Ribozyme Pharm Inc | Oligonucleotidos modificados en la posicion 2'-amido y 2'-peptido. |
| JPH11507056A (ja) | 1995-06-07 | 1999-06-22 | テラピン テクノロジーズ、インク． | グルタチオンアナログの代謝的効果 |
| US5968737A (en) | 1996-11-12 | 1999-10-19 | The University Of Mississippi | Method of identifying inhibitors of glutathione S-transferase (GST) gene expression |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP1072608B1 (en) | 1998-04-16 | 2005-06-15 | Teijin Limited | Glutathione derivatives and dosage forms thereof |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| WO2005019453A2 (en) * | 2001-05-18 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20070083945A1 (en) | 2000-03-10 | 2007-04-12 | Byrum Joseph R | Nucleic acid molecules and other molecules associated with plants |
| WO2001088191A1 (en) * | 2000-03-29 | 2001-11-22 | The United States Of America As Represented By The Department Of Veterans Affairs | A novel specific inhibitor of the cyclin kinase inhibitor p21?waf1/cip1¿ |
| US20030165843A1 (en) | 2000-07-28 | 2003-09-04 | Avi Shoshan | Oligonucleotide library for detecting RNA transcripts and splice variants that populate a transcriptome |
| ES2215494T5 (es) | 2000-12-01 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Moléculas de RNA pequeñas que median la interferencia de RNA |
| US20030099974A1 (en) | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US20040219600A1 (en) | 2002-12-13 | 2004-11-04 | Williams Robert Wood | Method for determining sensitivity to environmental toxins and susceptibility to parkinson's disease |
| WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| US20050142596A1 (en) | 2003-11-14 | 2005-06-30 | Krolewski Andrzej S. | Methods of diagnosing renal and cardiovascular disease |
| EP2514758B2 (en) | 2004-03-15 | 2021-06-23 | City of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| JP5697297B2 (ja) * | 2004-05-14 | 2015-04-08 | ロゼッタ ジノミクス リミテッド | マイクロｎａｓおよびその使用 |
| JP4965447B2 (ja) | 2004-08-26 | 2012-07-04 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 細菌由来のインタクトなミニセルを介した哺乳動物細胞への機能性核酸の送達 |
| US9393315B2 (en) * | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| WO2006068232A1 (ja) | 2004-12-22 | 2006-06-29 | Sapporo Medical University | 線維化抑制のための薬物担体および薬物担体キット |
| EP1874793A4 (en) | 2005-04-15 | 2008-12-24 | Univ Texas | DISTRIBUTION OF SIRNA BY NEUTRAL LIPID COMPOSITIONS |
| WO2007072220A2 (en) * | 2005-09-12 | 2007-06-28 | Aurelium Biopharma Inc. | Focused microarray and methods of diagnosing cancer |
| ES2324128A1 (es) * | 2005-09-29 | 2009-07-30 | Proyecto De Biomedicina Cima, S.L. | Metodo para el diagnostico de carcinoma hepatocelular mediante el empleo de marcadores moleculares. |
| EP1954820A1 (en) | 2005-10-25 | 2008-08-13 | Het Nederlands Kanker Instituut | Prediction of local recurrence of breast cancer |
| RU2448974C2 (ru) * | 2005-11-01 | 2012-04-27 | Элнилэм Фармасьютикалз, Инк. | РНКи-ИНГИБИРОВАНИЕ РЕПЛИКАЦИИ ВИРУСА ГРИППА |
| WO2007053696A2 (en) | 2005-11-01 | 2007-05-10 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
| AU2006308765B2 (en) | 2005-11-02 | 2013-09-05 | Arbutus Biopharma Corporation | Modified siRNA molecules and uses thereof |
| EP1948213B1 (en) | 2005-11-17 | 2009-02-04 | The Children's Medical Center Corporation | Methods to predict and prevent resistance to taxoid compounds |
| US7729737B2 (en) | 2005-11-22 | 2010-06-01 | Isense Corporation | Method and apparatus for background current arrangements for a biosensor |
| ES2419106T3 (es) | 2005-12-01 | 2013-08-19 | Pronai Therapeutics, Inc. | Formulación de liposomas anfóteros |
| JP5342834B2 (ja) * | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
| US9572886B2 (en) * | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
| US20070258952A1 (en) * | 2006-05-04 | 2007-11-08 | Baylor Research Institute | Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA |
| EP3578656B1 (en) | 2006-05-11 | 2021-01-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the pcsk9 gene |
| WO2008109432A2 (en) | 2007-03-02 | 2008-09-12 | The Board Of Regents Of The University Of Texas System | Therapeutic targeting of interleukins using sirna in neutral liposomes |
| TWI407971B (zh) | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
| WO2008124634A1 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
| AU2008270209B2 (en) | 2007-07-05 | 2012-05-17 | Arrowhead Pharmaceuticals, Inc. | dsRNA for treating viral infection |
| CN101842381A (zh) * | 2007-08-27 | 2010-09-22 | 波士顿生物医药公司 | 作为微小rna模拟物或抑制剂的不对称rna双链体的组合物 |
| WO2009033284A1 (en) * | 2007-09-14 | 2009-03-19 | Mcmaster University | Inhibitors of collagen biosynthesis as anti-tumor agents |
| ES2388196T3 (es) * | 2008-03-06 | 2012-10-10 | Rottapharm S.P.A. | Derivados de 2-aril- y 2-heteroaril-4H-1-benzopiran-4-ona-6-amidino para el tratamiento de artritis, cáncer y dolor relacionado |
| US20110223665A1 (en) | 2008-07-25 | 2011-09-15 | Alnylam Pharmaceuticals, Inc. | ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND |
| KR20110051214A (ko) * | 2008-07-30 | 2011-05-17 | 닛토덴코 가부시키가이샤 | 약물 담체 |
| RU2573409C2 (ru) * | 2009-11-04 | 2016-01-20 | Дзе Юниверсити Оф Бритиш Коламбиа | Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы |
| TWI543763B (zh) | 2009-12-09 | 2016-08-01 | 日東電工股份有限公司 | Ｈｓｐ４７表現之調節 |
| CA2828201A1 (en) | 2010-02-24 | 2011-09-01 | Bodysync, Inc. | Methods for determining gene-nutrient interactions |
| WO2011112954A1 (en) * | 2010-03-12 | 2011-09-15 | The Wistar Institute | Inhibition of p21 and use thereof for inducing tissue regeneration |
| US8372819B2 (en) * | 2010-04-11 | 2013-02-12 | Salk Institute For Biological Studies | Methods and compositions for targeting skip |
| US8828944B2 (en) | 2010-04-22 | 2014-09-09 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| WO2011138786A2 (en) | 2010-05-06 | 2011-11-10 | Stem Cell Medicine Ltd. | Stem cell bank for personalized medicine |
| JP5950428B2 (ja) * | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
| CN103221055A (zh) * | 2010-09-30 | 2013-07-24 | 日东电工株式会社 | Timp1和timp2表达的调节 |
| CN103370054A (zh) | 2010-11-09 | 2013-10-23 | 阿尔尼拉姆医药品有限公司 | 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法 |
| US9011903B2 (en) * | 2011-06-08 | 2015-04-21 | Nitto Denko Corporation | Cationic lipids for therapeutic agent delivery formulations |
| DK2718261T3 (en) * | 2011-06-08 | 2016-03-29 | Nitto Denko Corp | Compounds to target drug delivery and promote siRNA activity |
| TWI658830B (zh) * | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
| KR101786905B1 (ko) * | 2011-06-21 | 2017-10-19 | 닛토덴코 가부시키가이샤 | 아포토시스 유도제 |
| WO2013066485A2 (en) * | 2011-08-31 | 2013-05-10 | Asea Alexzander A | Compositions and methods for treatment of metastatic cancer |
| US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| US9631192B2 (en) * | 2011-11-17 | 2017-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Auto-recognizing therapeutic RNA/DNA chimeric nanoparticles (NP) |
| WO2013173307A1 (en) * | 2012-05-16 | 2013-11-21 | Neil Desai | Multi-target modulation for treating fibrosis and inflammatory conditions |
| US20140134158A1 (en) | 2012-05-22 | 2014-05-15 | Alberto Bardelli | Kras mutations and resistance to anti-egfr treatment |
| TWI654997B (zh) | 2012-06-08 | 2019-04-01 | 日商日東電工股份有限公司 | 用於治療劑輸送配方之脂質 |
| WO2013192364A1 (en) | 2012-06-22 | 2013-12-27 | The University Of Vermont And State Agricultural College | Treatments of oxidative stress conditions |
| EP2866835A1 (en) * | 2012-07-02 | 2015-05-06 | Fibrostatin, S.L. | Gpbp-1 inhibition and its therapeutic use |
| CA2879683C (en) | 2012-08-03 | 2023-02-14 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
| JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
| KR102255108B1 (ko) | 2013-03-08 | 2021-05-24 | 노파르티스 아게 | 활성제의 전달을 위한 지질 및 지질 조성물 |
| CN103695421B (zh) * | 2013-12-09 | 2016-06-15 | 浙江大学 | 一种特异抑制p21基因表达的siRNA及其应用 |
| US10792299B2 (en) * | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| WO2016104588A1 (ja) * | 2014-12-26 | 2016-06-30 | 日東電工株式会社 | 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物 |
| US10264976B2 (en) * | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| US20160187319A1 (en) | 2014-12-26 | 2016-06-30 | Nitto Denko Corporation | Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth |
| US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| PT3386519T (pt) * | 2015-12-13 | 2021-04-27 | Nitto Denko Corp | Estruturas de sirna para atividade elevada e redução de alvos extra |
| JP6899201B2 (ja) | 2016-06-23 | 2021-07-07 | 日東電工株式会社 | 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物 |
-
2015
- 2015-11-06 US US14/934,665 patent/US10264976B2/en not_active Expired - Fee Related
- 2015-12-28 US US14/979,567 patent/US10047110B2/en active Active
- 2015-12-28 CN CN201580071232.9A patent/CN107106564A/zh active Pending
- 2015-12-28 KR KR1020177020901A patent/KR20170093988A/ko unknown
- 2015-12-28 JP JP2017534275A patent/JP2018512373A/ja active Pending
- 2015-12-28 CA CA2971881A patent/CA2971881C/en active Active
- 2015-12-28 JP JP2017534274A patent/JP2018513104A/ja active Pending
- 2015-12-28 WO PCT/US2015/067560 patent/WO2016106405A1/en active Application Filing
- 2015-12-28 CN CN201580071234.8A patent/CN108024961A/zh active Pending
- 2015-12-28 EP EP20207751.7A patent/EP3798308A1/en active Pending
- 2015-12-28 BR BR112017013599-0A patent/BR112017013599A2/pt not_active Application Discontinuation
- 2015-12-28 AU AU2015369592A patent/AU2015369592B2/en active Active
- 2015-12-28 CN CN201580071210.2A patent/CN108064153A/zh active Pending
- 2015-12-28 JP JP2017534294A patent/JP6730285B2/ja active Active
- 2015-12-28 EP EP15874362.5A patent/EP3236975A4/en not_active Ceased
- 2015-12-28 AU AU2015369595A patent/AU2015369595A1/en not_active Abandoned
- 2015-12-28 AU AU2015369596A patent/AU2015369596A1/en not_active Abandoned
- 2015-12-28 KR KR1020177020894A patent/KR20170098929A/ko unknown
- 2015-12-28 WO PCT/US2015/067553 patent/WO2016106400A2/en active Application Filing
- 2015-12-28 JP JP2017534286A patent/JP6793649B2/ja active Active
- 2015-12-28 RU RU2017126601A patent/RU2017126601A/ru unknown
- 2015-12-28 BR BR112017013597-3A patent/BR112017013597B1/pt active IP Right Grant
- 2015-12-28 EP EP20156350.9A patent/EP3683309A1/en active Pending
- 2015-12-28 JP JP2017534287A patent/JP2018513669A/ja active Pending
- 2015-12-28 KR KR1020177020900A patent/KR20170096199A/ko unknown
- 2015-12-28 EP EP15874367.4A patent/EP3236973A4/en not_active Withdrawn
- 2015-12-28 WO PCT/US2015/067556 patent/WO2016106401A2/en active Application Filing
- 2015-12-28 US US14/979,568 patent/US10405749B2/en active Active
- 2015-12-28 RU RU2017126613A patent/RU2719185C2/ru active
- 2015-12-28 EP EP15874364.1A patent/EP3236945B1/en active Active
- 2015-12-28 WO PCT/US2015/067559 patent/WO2016106404A2/en active Application Filing
- 2015-12-28 CN CN201580071209.XA patent/CN107106592B/zh active Active
- 2015-12-28 RU RU2017126598A patent/RU2017126598A/ru not_active Application Discontinuation
- 2015-12-28 CA CA2972265A patent/CA2972265A1/en not_active Abandoned
- 2015-12-28 RU RU2017126610A patent/RU2756253C2/ru active
- 2015-12-28 CA CA2972268A patent/CA2972268A1/en not_active Abandoned
- 2015-12-28 US US14/979,573 patent/US9580710B2/en not_active Ceased
- 2015-12-28 EP EP15874361.7A patent/EP3236974B9/en active Active
- 2015-12-28 EP EP15874363.3A patent/EP3236976B1/en active Active
- 2015-12-28 US US14/979,566 patent/US9771582B2/en not_active Ceased
- 2015-12-28 CA CA2972270A patent/CA2972270A1/en not_active Abandoned
- 2015-12-28 KR KR1020177020898A patent/KR102527430B1/ko active IP Right Grant
- 2015-12-28 CN CN201580071191.3A patent/CN107106591B/zh active Active
- 2015-12-28 WO PCT/US2015/067561 patent/WO2016106406A2/en active Application Filing
- 2015-12-28 AU AU2015369598A patent/AU2015369598A1/en not_active Abandoned
- 2015-12-28 US US14/979,577 patent/US20160215286A1/en not_active Abandoned
- 2015-12-28 WO PCT/US2015/067557 patent/WO2016106402A1/en active Application Filing
- 2015-12-28 CN CN201580071233.3A patent/CN107108686B/zh active Active
- 2015-12-28 EP EP15874365.8A patent/EP3236969A4/en not_active Withdrawn
- 2015-12-28 JP JP2017534279A patent/JP6865169B2/ja active Active
- 2015-12-28 US US14/979,571 patent/US9695206B2/en active Active
- 2015-12-28 WO PCT/US2015/067558 patent/WO2016106403A2/en active Application Filing
- 2015-12-28 CN CN201580071081.7A patent/CN108064155B/zh active Active
- 2015-12-28 US US14/979,574 patent/US10047111B2/en not_active Ceased
- 2015-12-28 JP JP2017534297A patent/JP6457645B2/ja active Active
- 2015-12-28 EP EP15874366.6A patent/EP3240796B1/en active Active
-
2017
- 2017-04-17 US US15/489,650 patent/US20170218365A1/en not_active Abandoned
- 2017-06-27 US US15/634,771 patent/US10023597B2/en active Active
-
2019
- 2019-09-19 US US16/576,102 patent/USRE48887E1/en active Active
-
2020
- 2020-02-28 US US16/804,696 patent/USRE49229E1/en active Active
- 2020-08-11 US US16/990,860 patent/USRE49431E1/en active Active
-
2021
- 2021-11-11 JP JP2021183788A patent/JP7307137B2/ja active Active
- 2021-11-12 US US17/454,757 patent/US20220087531A1/en active Pending
-
2023
- 2023-06-29 JP JP2023106970A patent/JP2023123743A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512110A5 (ja) | ||
| JP2018512041A5 (ja) | ||
| JP2018512060A5 (ja) | ||
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| JP2018513668A5 (ja) | ||
| JP2016116520A5 (ja) | ||
| JP2018507711A5 (ja) | ||
| RU2017132895A (ru) | Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента | |
| JP2014527401A5 (ja) | ||
| JP2017536119A5 (ja) | ||
| JP2013226147A5 (ja) | ||
| JP2013535212A5 (ja) | ||
| JP2016522674A5 (ja) | ||
| JP2015519057A5 (ja) | ||
| AU2020200247A1 (en) | Organic compositions to treat KRAS-related diseases | |
| JP2015523853A5 (ja) | ||
| TWI752927B (zh) | 具高活性及減低脫靶之siRNA構造 | |
| JP2016520310A5 (ja) | ||
| JP2015511821A5 (ja) | ||
| JP2012223202A5 (ja) | ||
| JP2015128433A5 (ja) | ||
| JP2015532097A5 (ja) | ||
| WO2011142798A3 (en) | Methods of preparing targeted aptamer prodrugs | |
| WO2018152524A1 (en) | Toxic rnai active seed sequences for killing cancer cells | |
| JP2016521753A5 (ja) |